학술논문

Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
Document Type
Journal
Source
ANNALS OF ONCOLOGY; 2021, 32 pS896-pS897, 2p. Supplement: 5
Subject
Language
English
ISSN
15698041